Abstract: A composition comprising cannabis extract and melatonin is provided, along with formulations for delivering the composition to a subject. The composition can include a base ingredient such as polyethylene glycol, gelatin, tapioca and/or pectin; natural sweeteners; and oils of peppermint, lavender, ginger, citrus, mango, etc. The formulation can include tablets, capsules, lozenges, troches, suppositories, tinctures, a transdermal patch, a vaporizer, a metered dose inhaler, etc. The formulation avoids harmful preservatives (e.g., BHT, BHA), heavy metals and stabilizers while addressing sub-therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids (both acidic and neutral forms), terpenes and flavonoids.

Abstract: A cannabinoid troche including polyethylene glycol (or other base ingredients such as gelatin and/or pectin) and oils of peppermint, ginger, citrus, mango, etc., that is administered buccally and/or sublingually. This dosage form demonstrates an improved efficacy with reduced side effects when compared to formulations of cannabinoids in capsules, oral solutions, tinctures, sprays and edibles. The troches avoid harmful preservatives (e.g., BHT, BHA), heavy metals and stabilizers while addressing sub-therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids, terpenes and flavonoids. The use of peppermint oil (and others) in the troche shows improved efficacy above and beyond that which is expected or seen without its use. The troches further allow for accurate and reproducible therapeutic effects with ease of dosage adjustments.

Abstract: A composition comprising cannabis extract and melatonin is provided, along with formulations for delivering the composition to a subject. The composition can include a base ingredient such as polyethylene glycol, gelatin, tapioca and/or pectin; natural sweeteners; and oils of peppermint, lavender, ginger, citrus, mango, etc. The formulation can include tablets, capsules, lozenges, troches, suppositories, tinctures, a transdermal patch, a vaporizer, a metered dose inhaler, etc. The formulation avoids harmful preservatives (e.g., BHT, BHA), heavy metals and stabilizers while addressing sub-therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids (both acidic and neutral forms), terpenes and flavonoids.

Abstract: A cannabinoid troche including polyethylene glycol (or other base ingredients such as gelatin and/or pectin) and oils of peppermint, ginger, citrus, mango, etc., that is administered buccally and/or sublingually. This dosage form demonstrates an improved efficacy with reduced side effects when compared to formulations of cannabinoids in capsules, oral solutions, tinctures, sprays and edibles. The troches avoid harmful preservatives (e.g., BHT, BHA), heavy metals and stabilizers while addressing sub-therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids, terpenes and flavonoids. The use of peppermint oil (and others) in the troche shows improved efficacy above and beyond that which is expected or seen without its use. The troches further allow for accurate and reproducible therapeutic effects with ease of dosage adjustments.

Abstract: The present invention relates to a process for producing a ketamine ointment that is self-administered topically by a subject to alleviate neuropathic, sympathetic medicated pain and myofacial pain said subject is experiencing. The present invention is also utilized to improve the motor skills, alertness, sleeping habits, energy level and overall well-being of a subject suffering from Parkinson's disease.